

# Carcinogenesis

Integrative Cancer Research

Volume 30 Number 4 April 2009

[www.carcin.oxfordjournals.org](http://www.carcin.oxfordjournals.org)

Univ. of Minn.  
Bio-Medical  
Library

05 05 09

**Editor-in-Chief**

C.C.Harris, *Bethesda, MD, USA*

**Founding editors**

A.Dipple

C.Garner

**Editors****Cancer biology**

*Takashi Takahashi, Nagoya, Japan*

**Cancer prevention**

*Thomas Kensler, Baltimore, MA, USA*

**Carcinogenesis**

*Alan Clarke, Wales, UK*

**Molecular epidemiology**

*Curtis C.Harris, Bethesda, MD, USA*

# Carcinogenesis

## Integrative Cancer Research

**Editorial Board**

*B.Amati, Milan, Italy*

*S.Ambs, Bethesda, MD, USA*

*M.Barbacid, Madrid, Spain*

*S.A.Belinsky, Albuquerque, NM, USA*

*G.A.Calin, Houston, TX, USA*

*J.C.S.Chim, Hong Kong, China*

*D.C.Christiani, Boston, MA, USA*

*S.Chang, Houston, TX, USA*

*C.M.Croce, Columbus, OH, USA*

*O.Delattre, Paris, France*

*P.Dennis, Bethesda, MD, USA*

*A.Dinkova-Kostova, Dundee, UK*

*L.Donehower, Houston, TX, USA*

*R.DuBois, Nashville, TN, USA*

*S.Fischer, Smithville, TX, USA*

*D.Hunter, Boston, MA, USA*

*S.P.Jackson, Cambridge, UK*

*W.K.Kaufmann, Chapel Hill, NC, USA*

*F.J.Kaye, Bethesda, MD, USA*

*K.K.Khanna, Brisbane, Australia*

*D.P.Lane, Dundee, UK*

*S.Y.Leung, Hong Kong, China*

*X.Lu, Oxford, UK*

*M.Miyashita, Tokyo, Japan*

*H.Mukhtar, Madison, WI, USA*

*H.Nakagama, Tokyo, Japan*

*C.N.Ong, Singapore, Singapore*

*M.Oren, Rehovot, Israel*

*D.Palli, Florence, Italy*

*G.Pfeifer, Duarte, CA, USA*

*R.Ralhan, New Delhi, India*

*D.W.Rosenberg, Farmington, CT, USA*

*N.Rothman, Bethesda, MD, USA*

*V.Rotter, Rehovot, Israel*

*M.Serrano, Madrid, Spain*

*P.Shields, Washington, DC, USA*

*S.Singh, Pittsburgh, PA, USA*

*F.Slack, New Haven, CT, USA*

*Y.-J.Surh, Seoul, South Korea*

*V.Velculescu, Baltimore, MD, USA*

*L.Villa, São Paulo, Brazil*

*K.Vousden, Glasgow, UK*

*K.Wakabayashi, Tokyo, Japan*

*C.Wild, Leeds, UK*

*C.S.Yang, Piscataway, NJ, USA*

*P.-C.Yang, Taipei, Taiwan*

*M.You, St Louis, MO, USA*

*J.Yokota, Tokyo, Japan*

**Production Editor**

*Radha Dutia, Oxford University Press*

Published by Oxford University Press  
Oxford, UK

OXFORD UNIVERSITY PRESS

## REVIEW

- BRG1 and LKB1: tales of two tumor suppressor genes on chromosome 19p and lung cancer** S.Rodriguez-Nieto and M.Sanchez-Cespedes 547

## CANCER BIOLOGY

- Complex relationship between TCTP, microtubules and actin microfilaments regulates cell shape in normal and cancer cells** F.Bazile, A.Pascal, I.Arnal, C.Le Clainche, F.Chesnel and J.Z.Kubiak 555
- Leptin enhances cell migration in human chondrosarcoma cells through OBRI leptin receptor** S.-N.Yang, H.-T.Chen, H.-K.Tsou, C.-Y.Huang, W.-H.Yang, C.-M.Su, Y.-C.Fong, W.-P.Tseng and C.-H.Tang 566
- The oxysterol receptor LXR inhibits proliferation of human breast cancer cells** L.-L.Vedin, S.A.Lewandowski, P.Parini, J.-Å.Gustafsson and K.R.Steffensen 575
- Microparticles harboring Sonic Hedgehog promote angiogenesis through the upregulation of adhesion proteins and proangiogenic factors** R.Soleti, T.Benameur, C.Porro, M.A.Panaro, R.Andriantsitohaina and M.C.Martínez 580
- Tissue-resident stem cells promote breast cancer growth and metastasis** F.L.Muehlberg, Y.-H.Song, A.Krohn, S.P.Pinilla, L.H.Droll, X.Leng, M.Seidensticker, J.Ricke, A.M.Altman, E.Devarajan, W.Liu, R.B.Arlinghaus and E.U.Alt 589
- NDRG2 expression decreases with tumor stages and regulates TCF/β-catenin signaling in human colon carcinoma** Y.-J.Kim, S.Y.Yoon, J.-T.Kim, E.Y.Song, H.G.Lee, H.J.Son, S.Y.Kim, D.Cho, I.Choi, J.H.Kim and J.W.Kim 598

## MOLECULAR EPIDEMIOLOGY

- Variants in hormone-related genes and the risk of biliary tract cancers and stones: a population-based study in China** S.K.Park, G.Andreotti, L.C.Sakoda, Y.-T.Gao, A.Rashid, J.Chen, B.E.Chen, P.S.Rosenberg, M.-C.Shen, B.-S.Wang, T.-Q.Han, B.-H.Zhang, M.Yeager, S.Chanock and A.W.Hsing 606
- Dietary variables associated with DNA N7-methylguanine levels and O<sup>6</sup>-alkylguanine DNA-alkyltransferase activity in human colorectal mucosa** H.A.Billson, K.L.Harrison, N.P.Lees, C.N.Hall, G.P.Margison and A.C.Povey 615
- Nitric oxide synthase gene polymorphisms and prostate cancer risk** K.-M.Lee, D.Kang, S.K.Park, S.I.Berndt, D.Reding, N.Chatterjee, S.Chanock, W.-Y.Huang and R.B.Hayes 621
- Tobacco and estrogen metabolic polymorphisms and risk of non-small cell lung cancer in women** M.L.Cote, W.Yoo, A.S.Wenzlaff, G.M.Prysak, S.K.Santer, G.B.Claeys, A.L.Van Dyke, S.J.Land and A.G.Schwartz 626

## CANCER PREVENTION

- Grape seed extract inhibits VEGF expression via reducing HIF-1α protein expression** J.Lu, K.Zhang, S.Chen and W.Wen 636
- 15-Deoxy-Δ<sup>12,14</sup>-prostaglandin J<sub>2</sub> upregulates the expression of heme oxygenase-1 and subsequently matrix metalloproteinase-1 in human breast cancer cells: possible roles of iron and ROS** D.-H.Kim, J.-H.Kim, E.-H.Kim, H.-K.Na, Y.-N.Cha, J.H.Chung and Y.-J.Surh 645
- Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway** M.H.Jung, S.H.Lee, E.-M.Ahn and Y.M.Lee 655
- BTG3 tumor suppressor gene promoter demethylation, histone modification and cell cycle arrest by genistein in renal cancer** S.Majid, A.A.Dar, A.E.Ahmad, H.Hirata, K.Kawakami, V.Shahryari, S.Saini, Y.Tanaka, A.V.Dahiya, G.Khatri and R.Dahiya 662

## CARCINOGENESIS

- |  |  |            |
|--|--|------------|
| <b>The prolyl isomerase Pin1 interacts with a ribosomal protein S6 kinase to enhance insulin-induced AP-1 activity and cellular transformation</b> | N.Y.Lee, H.-K.Choi, J.-H.Shim, K.-W.Kang, Z.Dong and H.S.Choi  | <b>671</b> |
| <b>Tpl-2 kinase downregulates the activity of p53 and enhances signaling pathways leading to activation of activator protein 1 induced by EGF</b>  | P.Khanal, K.-Y.Lee, K.-W.Kang, B.S.Kang and H.S.Choi   | <b>682</b> |
| <b>Novel mechanism for obesity-induced colon cancer progression</b>  | J.M.Birmingham, J.V.Busik, F.M.Hansen-Smith and J.I.Fenton   | <b>690</b> |
| <b>Prostate stromal cells produce CXCL-1, CXCL-2, CXCL-3 and IL-8 in response to epithelia-secreted IL-1</b>                                       | I.Kogan-Sakin, M.Cohen, N.Paland, S.Madar, H.Solomon, A.Molchadsky, R.Brosh, Y.Buganim, N.Goldfinger, H.Klocker, J.A.Schalken and V.Rotter | <b>698</b> |
| <b>Sensitivity to NNKOAc is associated with renal cancer risk</b>  | J.Clague, L.Shao, J.Lin, S.Chang, Y.Zhu, W.Wang, C.G.Wood and X.Wu   | <b>706</b> |
| <b>Modulation of key regulators of mitosis linked to chromosomal instability is an early event in ochratoxin A carcinogenicity</b>                 | M.Adler, K.Müller, E.Rached, W.Dekant and A.Mally  | <b>711</b> |
| <br><b>LETTERS TO THE EDITOR</b>   |  |            |
| <b>The role of estrogens in melanoma and skin cancer</b>   | V.de Giorgi, C.Mavilia, D.Massi, S.Sestini, M.Grazzini, M.L.Brandi and T.Lotti   | <b>720</b> |
| <b>Re: Modulation of basal and squamous cell carcinoma by endogenous estrogen in mouse models of skin cancer</b>                                   | M.Mancuso, D.Gallo and A.Saran   | <b>721</b> |

## SUBSCRIPTIONS

A subscription to *Carcinogenesis* comprises 12 issues. All prices include postage, and for subscribers outside the UK delivery is by Standard Air. Advance Access contains papers that have recently been accepted, but have not yet been included within an issue. Advance Access is updated weekly.

### Annual subscription rate (Volume 30, 12 issues, 2009)

#### Institutional

Print edition and site-wide online access: £1136.00/\$2272.00/€1704.00

Print edition only: £1079.00/\$2158.00/€1619.00

Site-wide online access only: £1000.00/\$2000.00/€1500.00

#### Personal

Print edition and individual online access: £428.00/\$856.00/€642.00

Please note: US\$ rate applies to US & Canada, Euros applies to Europe, UK£ applies to UK and Rest of World

There may be other subscription rates available, for a complete listing please visit [www.carcin.oupjournals.org/subinfo/](http://www.carcin.oupjournals.org/subinfo/).

Full prepayment, in the correct currency, is required for all orders. Orders are regarded as firm and payments are not refundable. Subscriptions are accepted and entered on a complete volume basis. Claims cannot be considered more than FOUR months after publication or date of order, whichever is later. All subscriptions in Canada are subject to GST. Subscriptions in the EU may be subject to European VAT. If registered, please supply details to avoid unnecessary charges. For subscriptions that include online versions, a proportion of the subscription price may be subject to UK VAT. Personal rate subscriptions are only available if payment is made by personal cheque or credit card and delivery is to a private address.

The current year and two previous years' issues are available from Oxford University Press. Previous volumes can be obtained from the Periodicals Service Company, 11 Main Street, Germantown, NY 12526, USA. Email: [psc@periodicals.com](mailto:psc@periodicals.com). Tel: +1 (518) 537 4700. Fax: +1 (518) 537 5899.

For further information, please contact: Journals Customer Service Department, Oxford University Press, Great Clarendon Street, Oxford OX2 6DP, UK. Email: [jnls.cust.serv@oxfordjournals.org](mailto:jnls.cust.serv@oxfordjournals.org). Tel (and answerphone outside normal working hours): +44 (0)1865 353907. Fax: +44 (0)1865 353485. In the US, please contact: Journals Customer Service Department, Oxford University Press, 2001 Evans Road, Cary, NC 27513, USA. Email: [jnlorders@oxfordjournals.org](mailto:jnlorders@oxfordjournals.org). Tel (and answerphone outside normal working hours): 800 852 7323 (toll-free in USA/Canada). Fax: 919 677 1714. In Japan, please contact: Journals Customer Services, Oxford University Press, 4-5-10-8F, Shiba Minato-ku, Tokyo, 108-8386, Japan. Tel: +81 3 5444 5858. Fax: +81 3 3454 2929. E-mail: [custserv.jp@oxfordjournals.org](mailto:custserv.jp@oxfordjournals.org).

**Methods of payment.** Payment should be made: by cheque (to Oxford University Press, Cashiers Office, Great Clarendon Street, Oxford, OX2 6DP, UK); by bank transfer [to Barclays Bank Plc, Oxford Office, Oxford (bank sort code 20-65-18) (UK); overseas only Swift code BARC GB22 (GB£ Sterling Account no. 70299332, IBAN GB89BARC20651870299332; US\$ Dollars Account no. 66014600, IBAN GB27BARC20651866014600; EU€ EURO Account no. 78923655, IBAN GB16BARC20651878923655]; or by credit card (Mastercard, Visa, Switch or American Express).

*Carcinogenesis* (ISSN 0143-3334) is published monthly by Oxford University Press, Oxford, UK. Annual print subscription price is £1079.00/\$2158.00/€1619.00. *Carcinogenesis* is distributed by Mercury International, 365 Blair Road, Avenel, NJ 07001, USA. Periodical postage paid at Rahway, New Jersey and additional mailing entry points. US POSTMASTER: send address changes to *Carcinogenesis*, c/o Mercury International, 365 Blair Road, Avenel, NJ 07001, USA.

### Oxford Journals Environmental and Ethical Policies

Oxford Journals is committed to working with the global community to bring the highest quality research to the widest possible audience. Oxford Journals will protect the environment by implementing environmentally friendly policies and practices wherever possible. Please see <http://www.oxfordjournals.org/ethicalpolicies.html> for further information on Oxford Journals' environmental and ethical policies.

Articles in this journal are now assigned a Digital Object Identifier (DOI).

A DOI is a unique identifier of an article and can be used either to link to the online version of the article, or as additional information in a citation. Unlike a standard URL, the DOI of an article never changes, and so will work in perpetuity. To use a DOI as a link to the online version of an article, prefix the DOI with <http://dx.doi.org/> or go to the [dx.doi.org](http://dx.doi.org) website and enter the DOI. To include the DOI in a citation, insert the DOI at the end of the reference, prefixed with "doi:".

### Permissions

For information on how to request permissions to reproduce articles/information from this journal, please visit [www.oxfordjournals.org/permissions](http://www.oxfordjournals.org/permissions).

### Advertising

Advertising, inserts and artwork enquiries should be addressed to Advertising and Special Sales, Oxford Journals, Oxford University Press, Great Clarendon Street, Oxford, OX2 6DP, UK. Tel: +44 (0)1865 354767; Fax +44 (0)1865 353774; E-mail: [jnlsadvertising@oxfordjournals.org](mailto:jnlsadvertising@oxfordjournals.org)

### Disclaimer

Statements of fact and opinion in the articles in *Carcinogenesis* are those of the respective authors and contributors and not of *Carcinogenesis* or Oxford University Press. Neither Oxford University Press nor *Carcinogenesis* make any representation, express or implied, in respect of the accuracy of the material in this journal and cannot accept any legal responsibility or liability for any errors or omissions that may be made. The reader should make his/her own evaluation as to the appropriateness or otherwise of any experimental technique described.

© Oxford University Press 2009.

All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission of the Publishers, or a licence permitting restricted copying issued in the UK by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1P 9HE, or in the USA by the Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923. For those in the USA or Canada not registered with CCC, articles can be obtained by fax in 48 hours by calling: WISE for Medicine™ 1-800-667-WISE.

Typeset by TnQ Books and Journals Pvt. Ltd, Chennai, India.  
Printed in COS, Singapore.



## Microparticles harboring Sonic Hedgehog promote angiogenesis through the upregulation of adhesion proteins and proangiogenic factors

Raffaella Soletti<sup>†</sup>, Tarek Benameur<sup>†</sup>, Chiara Porro, Maria Antonietta Panaro<sup>1</sup>, Ramarosan Andriantsitohaina and Maria Carmen Martínez\*

Biologie Neuro-Vasculaire Intégrée, Centre National de la Recherche Scientifique, UMR 6214, Institut National de la Santé et de la Recherche Médicale, U771, Faculté de Médecine, Rue Haute de Reculée, Université d'Angers, F-49045 Angers, France and <sup>1</sup>Department of Human Anatomy and Histology, University of Bari, Bari I-70124, Italy

\*To whom correspondence should be addressed. Tel: +33 2 41 73 58 57; Fax: +33 2 41 73 58 95; Email: carmen.martinez@univ-angers.fr

Microparticles (MPs) are small fragments generated from the plasma membrane after cell stimulation or apoptosis. We have recently shown that MPs harboring the morphogen Sonic Hedgehog (MPs<sup>Shh+</sup>) correct endothelial injury by release of nitric oxide from endothelial cells [Agouni, Mostefai, Porro, Carusio, Favre, Richard, Henrion, Martínez and Andriantsitohaina (2007) FASEB J., 21, 2735–2741]. Here, we show that MPs<sup>Shh+</sup> induce the formation of capillary-like structures in an *in vitro* model using human endothelial cells, although they inhibited cell migration. Besides, MPs<sup>Shh+</sup> regulate cell proliferation. Both cell adhesion and expression of proteins involved in this process such as Rho A and phosphorylation of focal-activated kinase were increased by MPs<sup>Shh+</sup>, via a Rho-associated coiled-coil-containing protein kinase inhibitor-sensitive pathway. We demonstrate that MPs<sup>Shh+</sup> increase messenger RNA and protein levels of proangiogenic factors as measured by quantitative reverse transcription-polymerase chain reaction and western blot. In spite of vascular endothelial growth factor expression, conditioned media from endothelial cells treated avec MPs<sup>Shh+</sup> reduces angiogenesis. Interestingly, the effects induced by MPs<sup>Shh+</sup> on the formation of capillary-like structures, expression of adhesion molecules and proangiogenic factors were reversed after silencing of the Shh receptor, using small interfering RNA or when Sonic Hedgehog (Shh) signaling was pharmacologically inhibited with cyclopamine. Taken together, we show that Shh carried by MPs<sup>Shh+</sup> regulate angiogenesis probably through both a direct and an indirect mechanisms, and we propose that MPs harboring Shh may contribute to the generation of a vascular network in pathologies associated with tumor growth.

### Introduction

The morphogen Sonic Hedgehog (Shh) pathway is critical for normal growth. In addition to its role in embryonic development, it has been shown that, in adults, Shh network can participate in cell differentiation, proliferation and angiogenesis (1). Shh signal transduction is complex and not completely elucidated. In addition to the receptor, Patched-1, which represses the membrane protein Smoothened (Smo), other partners have been described such as Hedgehog-interacting protein (Hip) or Cam-related/downregulated by onco-

**Abbreviations:** FLT, fms-like tyrosine kinase; Hip, Hedgehog-interacting protein; HUVEC, human umbilical vein endothelial cell; ICAM, intercellular adhesion molecule; IL, interleukin; MP, microparticle; mRNA, messenger RNA; PBS, phosphate-buffered saline; FAK, focal adhesion kinase; ROCK, Rho-associated coiled-coil-containing protein kinase; RT-PCR, reverse transcription-polymerase chain reaction; Shh, Sonic Hedgehog; siRNA, small interfering RNA; Smo, smoothened; TGF, transforming growth factor; VEGF, vascular endothelial growth factor.

<sup>†</sup>These authors contributed equally to this work.

genes. While Hip is able to bind Shh and to block Shh signaling (2), Cam-related/downregulated by oncogene increases Shh signaling (3). Regarding angiogenesis, it has been reported that Shh pathway activation promotes *in vitro* capillary-like structures on Matrigel® (4) but also *in vivo* neo-vascularization (5). Moreover, recent data showed that the effects of Shh recombinant protein through Smo receptor in both angiogenesis and specification of neuronal fates are mediated by the phosphatidylinositol 3-kinase/Akt but not protein kinase C pathways (4,6,7). Also, Hip is downregulated on human endothelial cells during capillary-like structure formation suggesting that regulation of level expression of Hip may play a role in angiogenesis (2).

Taking in consideration that angiogenesis is an essential process of cells from cardiovascular system during diseases associated with ischemia or for tumor growth, the role of Shh-induced angiogenesis in these pathologies is critical. Thus, it has been shown that Shh gene therapy may have considerable therapeutic potential by improving cardiac function in either ischemia or infarct models and wound healing in diabetes (8,9). In parallel to the effects of Shh cascade in angiogenesis, uncontrolled activation of the Hedgehog-signaling pathway is a causal factor in many cancers (10) and upregulation of Shh-related proteins has been shown in human tumors such as pancreatic adenocarcinoma, basal cell carcinoma, glioma and prostate cancer (11–14).

Tumor cells but also blood and vessel wall cells are able to release large amounts of small plasma membrane fragments called microparticles (MPs). MPs are responsible, at least in part, to cancer-associated thrombosis because they harbor at their surface tissue factor and other components necessary for thrombus formation (15). Thus, MPs may represent a sign of vascular complications in patients with lung and gastric cancer (16,17). These authors have reported enhanced circulating monocyte- and platelet-derived MPs in patients with lung cancer. In addition, levels of P-selectin associated to platelet MPs and tissue factor generated from cancer cells are increased indicating that proteins involved in hemostasis are elevated in patients with cancer (18) and may represent a tool for exacerbated thrombosis. Also, through proteins carried by MPs from tumor cells, such as urokinase, CD147 or sphingomyelin, MPs can modify the adhesive and invasive properties of target cells (19) or the angiogenic activity of endothelial cells (20). Moreover, it has been shown that platelet MPs enhance the *in vitro* invasive potential of breast cancer cell lines and induce metastasis and angiogenesis in lung cancer (21,22). These data suggest that MPs transfer a transcellular signal that may allow tumor progression. In this context, MPs from acute myelogenous leukemia patients functionally transferred C-X-C chemokine receptor to HL-60 cells and increased their chemotaxis and homing to the bone marrow of immunodeficient mice (23).

We have recently shown that MPs generated *in vitro* from human apoptotic/stimulated lymphocytes express Shh (MPs<sup>Shh+</sup>) at their surface and induce cell differentiation (24). In addition, this type of MPs is able to stimulate nitric oxide production from endothelial cells by direct activation of the Shh and phosphatidylinositol 3-kinase pathways (25). Thus, MPs<sup>Shh+</sup> could represent a potential tool to modulate angiogenesis through their direct action on endothelial cells. Here, we studied the effects of MPs<sup>Shh+</sup> on *in vitro* angiogenesis using a human model of endothelial cells. For this, we have investigated MPs<sup>Shh+</sup> effects on migration, proliferation, adhesion and formation of capillary-like structures as well as the angiogenic factors produced by endothelial cells under MPs<sup>Shh+</sup> treatment.

### Materials and methods

#### MP production

The human lymphoid CEM T cell line (American Type Culture Collection, Manassas, VA) was used for MP production. Cells were seeded at 10<sup>6</sup> cells/ml and cultured in serum-free X-VIVO 15 medium (Lonza, Walkersville, MD).

MPs were produced as described previously (24,25). Briefly, CEM cells were treated with phytohemagglutinin (5 µg/ml; Sigma-Aldrich, St Louis, MO) for 72 h and then with phorbol-12-myristate-13 acetate (20 ng/ml; Sigma-Aldrich) and actinomycin D (0.5 µg/ml; Sigma-Aldrich) for 24 h. A supernatant was obtained by centrifugation at 750g for 15 min and then at 1500g for 5 min to remove cells and large debris, respectively. MPs from the supernatant were washed after three centrifugation steps (45 min at 14 000g) and recovered in 400 µl NaCl (0.9% wt/vol). Washing medium for the last supernatant was used as control. Determination of the amount of MPs was carried out by measuring MP-associated proteins, using the method of Lowry, with bovine serum albumin (Sigma-Aldrich) as the standard. Shh carried by MPs was detected by western blot as described previously (24) (data not shown).

#### Cell culture

The Eahy 926 endothelial cell line was maintained at 37°C in a humidified incubator gassed with 5% CO<sub>2</sub> in air and was cultured in growth medium (Dulbecco's modified Eagle's medium:Ham's F-12, 1:1; Lonza) supplemented with 1% L-glutamine, 1% non-essential amino acids, 1% Na-pyruvate, 1% streptomycin/penicillin (Lonza), 1% hypoxanthine, aminopterin, thymidine (Sigma-Aldrich) and 10% of heat-inactivated fetal bovine serum (Invitrogen, Cergy Pontoise, France). Also, freshly delivered umbilical cords were obtained from a nearby hospital. Human umbilical vein endothelial cells (HUVECs) were obtained as described previously (26) and grown on plastic flasks in MCB2 131 medium containing 1% L-glutamine, 1% streptomycin/penicillin, 500 ng/l epidermal growth factor, 1 µg/l basic fibroblast growth factor, supplemented with 10% of heat-inactivated fetal bovine serum. HUVECs were used at the second to fourth passage. Cells were grown for 24 h in the absence or presence of 10 µg/ml MPs preincubated or not for 30 min with Smo inhibitor cyclopamine (30 µM; Biomol International, Plymouth Meeting, PA) or Rho-associated coiled-coil-containing protein kinase (ROCK) inhibitor (Y-27632, 10 µM). All agents were used at concentrations at which no cytotoxicity was observed, as deduced from Trypan blue exclusion and with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. In our previous study, treatment of endothelial cells *in vitro* with 10 µg/ml MPs for 24 h corresponded to the concentration and time required to obtain nitric oxide release from endothelial cells (25). Thus, all the experiments of the present work were performed under these conditions.

#### *In vitro* capillary network formation on Matrigel®

After 24 h of incubation with MPs in the absence or in the presence of the inhibitor cyclopamine, small interfering RNA (siRNA) (see below), basic fibroblast growth factor (Peprotech, Rocky Hill, NJ, 10 ng/ml) or vascular endothelial growth factor (VEGF) (Santa Cruz Biotechnology, Santa Cruz, CA, 20 ng/ml), Eahy 926 cells and HUVECs were detached with trypsin ethylenediaminetetraacetic acid (Lonza). Cells were seeded with a density of  $150 \times 10^3$  cells per well precoated with Matrigel® (Sigma-Aldrich). Briefly, 100 µl of Matrigel® substrate diluted with serum-free medium (1:1 dilution) was added into a four-well plate and allowed to solidify for 1 h at 37°C. Then, cells were incubated with medium containing 10% of fetal bovine serum and allowed to adhere for 1 h after which the different stimuli were added. Tube formation was examined by phase-contrast microscopy (MOTIC AE21) after 4

and 24 h and quantified using ImageJ software. To determine whether mediators secreted by cells treated with MPs are able to induce capillary formation, HUVECs were treated with MPs or cyclopamine + MPs as described above and culture media were removed. Then, HUVECs were treated with the conditioned medium for 24 h, and tube formation was determined as described above.

#### RNA interference and transient transfection

In order to silencing Patched-1, the Shh receptor, siRNA duplexes specific for human Patched-1 and control, non-silencing siRNA was obtained from Santa Cruz Biotechnology. Transient transfection of Eahy 926 endothelial cells and HUVECs was done according to the manufacturer's protocol. Briefly, cells were seeded in six-well plates, grown for 24 h (60% confluence) and then transiently transfected with 100 nM of Patched-1-specific or control siRNA using the transfection reagent provided, which also served as control without siRNA. Medium was replaced 24 h later by fresh medium and cells were grown for an additional 24 h, prior to either western blot analysis of Patched-1 expression or functional studies. After siRNA transfection, Patched-1 downexpression was >80% (data not shown) as previously illustrated by Agouni *et al.* (25).

#### Western blot

After treatment, cells were homogenized and lysed. Proteins (20 µg) were separated on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Blots were probed with anti-Rho A (Santa Cruz Biotechnology), anti-p-focal adhesion kinase (Y925) (p-FAK, Cell Signaling, Danvers, MA), anti-Patched-1, intercellular adhesion molecule (ICAM)-1, VEGF, fms-like tyrosine kinase (FLT)-1 and interleukin (IL)-1β (Santa Cruz Biotechnology) antibodies. Monoclonal anti-β-actin antibody (Sigma-Aldrich) was used at 1:2000 dilution to visualize protein gel loading. The membranes were then washed at least three times in Tris buffer solution containing 0.05% Tween and incubated for 1 h at room temperature with the appropriate horseradish peroxidase-conjugated secondary antibody (Amersham Biosciences, Piscataway, NJ). The protein-antibody complexes were detected by Enhanced chemiluminescence plus (Amersham Biosciences) according to the protocol of the manufacturer.

#### Migration assay

Eahy 926 cells were seeded and grown to confluence in cell culture medium. After 24 h of serum starvation, cells were rinsed three times with serum-free

Table I. Genes analyzed by RT-PCR (alphabetical order)

α5 integrin	FGF1	FLT-1	MCP-1	SDF1
ANG1	FGF2	FLT-4	MMP1	TGFβ1
ANG2	FGF3	HGF	MMP2	TGFβ2
angiogenin	FGF5	ICAM-1	PDGFA	Tie1
β3 integrin	FGF7	IGF-1	PDGFB	Tie2
CCR2	FGF8	IL-1β	PDGFRb	TSP1
edg1	FGF10	IL-6	PECAM-1	VCAM-1
ephrin b2	FGFR1	IL-8RB	PEDF	VE-cadherin
E-selectin	FGFR2	KDR	RANTES	VEGF (A-D)





Fig. 1. MPs promote *in vitro* tube formation of Eahy 926 endothelial cells. Phase-contrast micrographs showing that 10 µg/ml MPs carrying Shh induce network formation on Matrigel® in Eahy 926 cells. Silencing Shh pathway by either the pharmacological inhibitor cyclopamine (30 µM) or siRNA of the Shh receptor, Patched-1, prevented MP-induced capillary formation. However, siRNA scrambled had no effect on *in vitro* angiogenesis evoked by MPs. Reproducible data were obtained from four independent experiments.



**Fig. 2.** MPs enhance *in vitro* tube formation of HUVECs. (A) Phase-contrast micrographs showing that 10  $\mu$ g/ml MPs carrying Shh favor network formation on Matrigel® in HUVECs. Silencing Shh pathway with the pharmacological inhibitor cyclopamine (Cycl, 30  $\mu$ M) or siRNA of the Shh receptor, Patched-1, prevented MP-induced capillary formation. Conditioned media obtained from HUVECs treated with MPs were unable to induce capillary formation. VEGF (20 ng/ml) was used as positive control. (B) Capillary length was used to quantify angiogenesis. Reproducible data were obtained from three independent experiments. \* $P < 0.05$  versus in the absence of MPs<sup>Shh+</sup>. # $P < 0.05$  versus in the presence of MPs<sup>Shh+</sup> alone or VEGF alone.

medium and then incubated with supplemented medium. The monolayer cell was wounded with a sterile pipet tip to make a gap as described previously (27). Then, detached cells were removed by washing, and cells were cultured in the absence or in the presence of MPs, MPs with cyclopamine or VEGF (20 ng/ml) as positive control. After 48 h, three selected non-adjacent fields at the lesion border were acquired using a  $\times 10$  phase objective on an inverted microscope (MOTIC AE21).

#### Confocal microscopy

After treatment, cultured cells were fixed with CELLFIX 1 $\times$  (BD Biosciences, Le Pont de Claix, France) solution for 15 min at room temperature in culture dishes, permeabilized with 0.1% Triton X-100 in phosphate-buffered saline (PBS) and then blocked with 5% non-fat milk in PBS for 1 h at room temperature. The cells were treated with a rabbit polyclonal p-FAK (Y925) antibody



or mouse monoclonal anti-Rho A antibody in 5% non-fat milk in PBS for 1 h at room temperature. After washing with PBS, cells were treated with Alexa 488-conjugated goat anti-rabbit antibody (Interchim, Montlucan, France) and Alexa 488-conjugated goat anti-mouse (Interchim) in 5% non-fat milk in PBS for 1 h. In another set of experiment, tetramethylrhodamine isothiocyanate-phalloidin (Sigma-Aldrich) was used in order to label actin fibers. Briefly after treatments, cells were fixed with 2% paraformaldehyde and then stained with phalloidin (50  $\mu$ g/ml) for 90 min at room temperature. After washing with PBS, the cells were mounted and visualized with a confocal microscopy (MRC-1024ES confocal equipment mounted on a Nikon Eclipse T3 300 microscope) in the Service Commun d'Imagerie et d'Analyses Microscopiques from Angers University. All images were acquired using a  $\times 60$  objective.

#### Quantitative real-time reverse transcription-polymerase chain reaction analysis

Eahy 926 cells were grown for 24 h in the absence or presence of 10  $\mu$ g/ml MPs preincubated or not with cyclopamine. Cells were detached using trypsin and after two subsequent steps of centrifugation at 500g for 10 min, the pellet containing cells were frozen in liquid N<sub>2</sub> and used to investigate the expression of messenger RNA (mRNA) for 46 transcripts related to angiogenesis by real-time reverse transcription-polymerase chain reaction (RT-PCR) (Table I). RT-PCR analyses were carried out by Service Commun de Cytométrie et d'Analyses Nucléotidiques from Angers University, using a Chromo 4™ (Bio-Rad, Hercules, CA) and SYBR Green detection. Primers were designed using Primer3 software ([http://frodo.wi.mit.edu/cgi-bin/primer3/primer3\\_www.cgi](http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi)). Quanti-


fications were realized according to the  $\Delta$ Ct method and the relative gene expression levels were normalized using the geometric mean of three house-keeping genes as described previously (28).

#### Proliferation assay

Effects of MPs on proliferation on Eahy 926 cells or HUVECs were analyzed by using CyQUANT Cell Proliferation Assay Kit (Molecular Probes, Eugene, OR). Briefly,  $10 \times 10^3$  cells per well were seeded into 96-well plates and allowed to attach overnight and then cells were treated with MPs for 24 h. After growth medium removal, dye-binding solution was added into each microplate well and cells were incubated at 37°C for 30 min. The fluorescence levels were read on a fluorescent microplate reader (Synergy HT, Biotek, Winooski, VT) with filters for  $\sim 485$  nm excitation and  $\sim 530$  nm emission.

#### Adhesion assay

Evaluation of adherent cells was performed using crystal violet staining (29). For adhesion experiments,  $10 \times 10^3$  cells per well were seeded into 96-well plates for 24 h before addition of the stimuli, in the absence or in the presence of coated fibrinogen (Sigma-Aldrich, 100  $\mu$ g/ml) (30). After 24 h of incubation, the plate was shaken for 15 s. The supernatant with non-adherent cells was removed by three washes with washing buffer (0.1% bovine serum albumin in medium without serum). Attached cells were fixed with 4% of paraformaldehyde for 15 min at room temperature. Cells were rinsed two times with washing buffer, stained with crystal violet (Sigma-Aldrich) (1 mg/ml in 2% of ethanol) for 10 min at room temperature and extensively washed with



**Fig. 3.** MPs<sup>Shh+</sup> decrease cell migration and proliferation. (A) Ten micrograms per milliliter MPs<sup>Shh+</sup> treatment decrease cell migration when compared with the control conditions (in the absence of MPs<sup>Shh+</sup>). The effects of MPs<sup>Shh+</sup> were not modified by cyclopamine (30  $\mu$ M). VEGF (20 ng/ml) was used as positive control. Reproducible data were obtained from four independent experiments. (B) In Eahy cells, antiproliferative effects of MPs<sup>Shh+</sup> were not inhibited by treatment with cyclopamine (Cycl), whereas VEGF was able to increase cell proliferation by a mechanism insensitive to cyclopamine. (C) MPs<sup>Shh+</sup> treatment decreased proliferation on HUVECs. Results are means  $\pm$  SEMs from six independent experiments. \* $P < 0.05$  versus in the absence of MPs<sup>Shh+</sup>.

distilled water. Then sodium dodecyl sulfate 2% was added and incubated for 30 min at room temperature. Absorbance was then evaluated using a microplate reader at 550 nm (Sinegy HT Biotek).

#### Statistical analysis

Data are represented as mean  $\pm$  SEM,  $n$  represents the number of experiments repeated at least in triplicate. Statistical analyses were performed by Mann-Whitney  $U$ -tests (non-parametric).  $P < 0.05$  was considered to be statistically significant.

## Results

### *MPs<sup>Shh+</sup> promote the formation of capillary-like structures*


As shown in Figure 1, in the absence of treatment, endothelial Eahy cells failed to organize in capillary-like structures. After 24 h of treatment with MPs<sup>Shh+</sup>, endothelial Eahy cells reorganized and formed capillaries on Matrigel®. Although in the absence of treatment HUVECs were able to form capillaries, MPs<sup>Shh+</sup> enhanced capillary-like structure formation as illustrated by the capillary length measurement (Figure 2B). In order to determine whether Shh accounts for the effects evoked by MPs<sup>Shh+</sup>, we examined the effect of Shh inhibition on MPs<sup>Shh+</sup>-induced angiogenesis. Treatment of endothelial cells either with the selective Shh inhibitor, cyclopamine (30  $\mu$ M), or siRNA to Shh receptor, Patched-1, resulted in an abolition of MPs<sup>Shh+</sup> effects on capillary-like structure formation in both Eahy cells and HUVECs (Figures 1 and 2). It should be noted that cyclopamine alone or siRNA scrambled had no effect on endothelial cell angiogenesis. Furthermore, VEGF (20 ng/ml) promoted formation of capillaries on HUVECs and these effects were

partially inhibited by cyclopamine, suggesting a link between VEGF and Shh pathways (Figure 2). In addition, conditioned media from HUVECs treated with MPs<sup>Shh+</sup> reduced the ability of these cells to form capillary-like structures (Figure 2A). Together, these findings suggest that the effects of MPs<sup>Shh+</sup> are directly mediated by the Shh cascade.

### *MPs<sup>Shh+</sup> reduce both endothelial cell migration and proliferation*

Migration of endothelial cells, which allows cells to disseminate from the pre-existing vessel to form new vessels, contributes to angiogenesis. We studied the effects of MPs<sup>Shh+</sup> on endothelial cell migration using a model of wound healing. MPs<sup>Shh+</sup> slightly reduced migration of endothelial Eahy cells, which was not affected by cyclopamine (Figure 3A). Similar results were obtained in HUVECs treated with MPs<sup>Shh+</sup> (data not shown). As positive control, VEGF was able to increase endothelial cell migration (Figure 3A).

Also, the effect of MPs<sup>Shh+</sup> on cell proliferation was investigated since this process represents a critical step in angiogenesis. Figure 3B and C illustrates the antiproliferative effect of MPs<sup>Shh+</sup>. MPs<sup>Shh+</sup> were able to reduce cell proliferation by  $\sim 20$  and 30% for Eahy cells (Figure 3B) and HUVECs (Figure 3C), respectively. In addition, cyclopamine treatment did not modify the inhibitory effect of MPs<sup>Shh+</sup> on cell proliferation. These data indicate that Smo receptor is not implicated in the MPs<sup>Shh+</sup> effects on endothelial cell proliferation. Furthermore, VEGF treatment induces an increase of cell proliferation, which was not affected by cyclopamine treatment (Figure 3B).



**Fig. 4.** MPs<sup>Shh+</sup> increase adhesion of endothelial cells. Ten micrograms per milliliter MPs<sup>Shh+</sup> enhance the number of Eahy cells (A) and HUVECs (B) that resulted positive to crystal violet staining. Treatment with the ROCK inhibitor (Y-27632, 10  $\mu$ M) but not cyclopamine (Cycl, 30  $\mu$ M) prevented the MPs<sup>Shh+</sup>-induced increase of endothelial adhesion. In fibrinogen (Fg)-coated plates, adhesion was enhanced by MPs<sup>Shh+</sup> treatment. Results are means  $\pm$  SEMs from six independent experiments. \* $P < 0.05$  versus in the absence of MPs<sup>Shh+</sup>. # $P < 0.05$  versus in the presence of MPs<sup>Shh+</sup> alone. (C) Quantitative RT-PCR analysis was conducted on total RNA from six independent Eahy cultures. ICAM-1 mRNA expression levels were enhanced by MPs<sup>Shh+</sup> treatment. Cyclopamine partially reversed the MPs<sup>Shh+</sup>-induced increase of ICAM-1 mRNA expression. \* $P < 0.05$  versus in the absence of MPs<sup>Shh+</sup>. # $P < 0.05$  versus in the presence of MPs<sup>Shh+</sup> alone. (D) Western blot showing ICAM-1 protein level expression in the presence of MPs<sup>Shh+</sup>. ICAM-1 protein expression was increased by MPs<sup>Shh+</sup> treatment. \*\* $P < 0.01$  versus in the absence of MPs<sup>Shh+</sup>.

*MPs<sup>Shh+</sup> upregulate proteins involved in cell adhesion through Rho A and Shh pathways*

Adhesion assay using crystal violet shows that MPs<sup>Shh+</sup> increased adhesion in both EaHy and HUVECs cells (Figure 4A and B, respectively). Although cyclopamine was not able to reduce the effects of MPs<sup>Shh+</sup> on cell adhesion, inhibition of ROCK by Y-27632 (10  $\mu$ M) decreased MPs<sup>Shh+</sup>-induced cell adhesion (Figure 4A). Specific transcripts for the ICAM-1 measured by real-time quantitative RT-PCR were enhanced by MPs<sup>Shh+</sup> treatment and this effect was abolished by cyclopamine (Figure 4C). The increased ICAM-1 mRNA expression upon MPs<sup>Shh+</sup> treatment was associated with enhanced protein expression (Figure 4D). In order to confirm the ability of MPs<sup>Shh+</sup> to favor cell adhesion, we assessed the effects of MPs<sup>Shh+</sup>-induced adhesion on EaHy cells using fibrinogen-coated plates. Under these conditions, adhesion was enhanced by MPs<sup>Shh+</sup> treatment, suggesting an interaction between fibrinogen and its receptor, ICAM-1 (Figure 4A).

Then, the effect of Y-27632 on the expression and activation of proteins linked to cell adhesion was investigated. MPs<sup>Shh+</sup> induced an increase in Rho A expression and FAK phosphorylation as evidenced by immunolabeling and western blot. These effects were inhibited not only by Y-27632 but also by cyclopamine (Figure 5A–C). In addition, labeling of actin fibers with phalloidin showed that MPs<sup>Shh+</sup> induced the formation of stress fibers, which was reversed by Y-27632 treatment (data not shown). These results suggest that proteins such as Rho A and FAK, which are involved in cell adhesion, are upregulated by MPs<sup>Shh+</sup> through both ROCK and Shh pathways, despite the existence of pathways not associated with Smo receptor activation.


*MPs<sup>Shh+</sup> upregulate proangiogenic factors through the activation of the Shh pathway*

Angiogenic factors were analyzed by real-time quantitative RT-PCR using a panel of different human angiogenic factor mRNA. Among the 46 transcripts studied (Table I), those for proangiogenic factors such as hepatocyte growth factor, metalloproteinase-1, IL-1 $\beta$  and VEGF A and its receptor FLT-1 were increased by MPs<sup>Shh+</sup> treatment. These effects were partially inhibited by cyclopamine. In contrast, transforming growth factor (TGF)- $\beta$ 2 mRNA was reduced by MPs<sup>Shh+</sup>, independently of the inhibition of the Shh pathway (Figure 6A).


In order to confirm that MPs<sup>Shh+</sup> treatment upregulated proangiogenic factors, protein levels of VEGF, FLT-1 and IL-1 $\beta$  were analyzed. Western blot analyses show that neither IL-1 $\beta$  nor FLT-1 protein levels were increased when cells were incubated in the presence of MPs<sup>Shh+</sup>. In contrast, VEGF protein expression was increased by MPs<sup>Shh+</sup> and these effects were reversed by cyclopamine (Figure 6B).

### Discussion

In the present study, we demonstrate that MPs generated from activated/apoptotic T cells harboring Shh differentially regulate the steps implicated in angiogenesis. Thus, MPs<sup>Shh+</sup> increased capillary-like formation through the increase of cell adhesion, the upregulation of proteins such as ICAM-1 and Rho A and the activation of FAK and proangiogenic factors, mainly VEGF, via the activation of the Shh pathway. In addition, the effects induced by MPs<sup>Shh+</sup> on cell adhesion were dependent on ROCK pathway. However, MPs<sup>Shh+</sup> reduced cell



**Fig. 5.** MPs<sup>Shh+</sup> increase expression of Rho A and phosphorylation of FAK. (A) Immunofluorescence staining of endothelial cells for Rho A and p-FAK showed upregulation of Rho A expression and activation of FAK pathway after MPs<sup>Shh+</sup> treatment. These effects were reversed by either cyclopamine (Cycl, 30  $\mu$ M) or Y-27632 (10  $\mu$ M) treatment. (B and C) This was confirmed by western blot.  $\beta$ -Actin control is included. Data are representative of five separate blots, and the densitometry values are expressed in arbitrary units (A.U.) as mean  $\pm$  SEM. \* $P$  < 0.05, \*\* $P$  < 0.01 versus in the absence of MPs<sup>Shh+</sup>. # $P$  < 0.05 versus in the presence of MPs<sup>Shh+</sup> alone.



**Fig. 6.** MP<sup>Shh+</sup> modify mRNA and protein expressions of angiogenic factors. (A) Quantitative RT-PCR analysis was conducted on total RNA from six independent Eahy cultures. HGF, MMP 1, VEGF A, FLT1 and IL-1β mRNA expression levels were enhanced by MP<sup>Shh+</sup> treatment. Cyclopamine partially reversed the MP<sup>Shh+</sup>-induced increase of VEGF A, IL-1β and MMP 1 mRNA expressions. TGF-β2 mRNA expression was reduced by MP<sup>Shh+</sup> treatment. \**P* < 0.05 versus in the absence of MP<sup>Shh+</sup>. #*P* < 0.05 versus in the presence of MP<sup>Shh+</sup> alone. (B) Western blot showing the protein expression of IL-1β, VEGF A and FLT-1. \**P* < 0.05 versus in the absence of MP<sup>Shh+</sup>.

migration and proliferation through the mechanisms independent of Smo receptor activation. These data suggest that MPs transfer a biological message carried by Shh that can account for a large number of events associated with angiogenesis.

In tumor-associated angiogenesis, angiogenic factors secreted by endothelial and tumor cells stimulate endothelial cells to degrade the vascular basal membrane and migrate into surrounding tissues promoting the proliferation of solid tumors (31). Here, we showed that MP<sup>Shh+</sup> are able to increase expression level of mRNA of proangiogenic factors such as VEGF A, FLT-1, ICAM-1, metalloproteinase-1, IL-1β and hepatocyte growth factor, and these effects were Smo dependent. Among these factors, the complex VEGF A-FLT-1 represents the major player in angiogenesis initiation by inducing endothelial nitric oxide production (32), in parallel to the increase of ICAM-1 expression (33). Surprisingly, while protein level of VEGF was increased by MP<sup>Shh+</sup> treatment, its receptor, FLT-1, did not. Several hypotheses can explain these results. On one hand, it is plausible that expression of VEGF receptor is delayed when compared with its mRNA expression. On the other hand, it is possible that the increase of translation to FLT-1 protein is performed at low levels that may be below the threshold of detection for the antibody

used in the present study, as described previously in astrocytes by Krum *et al.* (34). Nevertheless, the proangiogenic factor VEGF is overexpressed suggesting that MP<sup>Shh+</sup> could induce angiogenesis through a VEGF-dependent mechanism. However, the conditioned media obtained from cells treated with MP<sup>Shh+</sup> was not able to favor formation of capillaries. These results indicate that, probably, the amount of proangiogenic factors produced by MP<sup>Shh+</sup> may not be sufficient to induce angiogenesis and alternatively a direct stimulation of endothelial cells by Shh associated with MPs is mandatory to favor formation of capillary-like structures. Also, MMPs are essential for angiogenesis due to their ability to degrade the components of the extracellular matrix and thus MMPs participate in the remodeling of basement membranes (35). Moreover, IL-1β induces VEGF A expression through the phosphatidylinositol 3-kinase pathway (36). Although protein levels of IL-1β are not increased, as for VEGF receptor, IL-1β protein expression might be delayed when compared with its mRNA expression. Finally, hepatocyte growth factor is identified as a member of angiogenic growth factors with a potent action on human endothelial cells (37). Interestingly, expression of TGF-β2 was downregulated by MP<sup>Shh+</sup>. TGF-β acts as a tumor suppressor early in carcinogenesis, but then switches to

a tumor promoter later by affecting both the cancer cells and the tumor microenvironment (38). Both TGF- $\beta$ 2 and Shh are involved in processes during embryonic development and cancer. Indeed, it has been recently shown that TGF- $\beta$  induces the expression of the Hedgehog-signaling molecules Gli1 and Gli2 in various cancer cell lines independently of the Hedgehog receptor activation (39). The fact that MP<sup>Shh+</sup> reduced TGF- $\beta$ 2 expression may favor angiogenesis. Regarding the effects of Shh on angiogenic factors, it has been reported that recombinant Shh is able to induce the expression of angiopoietin-1 and reduce angiopoietin-2 expression in embryonic fibroblast cells (40). In contrast, angiopoietin-1, angiopoietin-2 and VEGF are overexpressed by recombinant Shh treatment in human fibroblasts (5), whereas Shh-deficient mice present a downregulation of mRNA expression of angiopoietin-1 but not of angiopoietin-2 and VEGF (41). Altogether, the present study shows that Shh carried by MPs acts on a large number of target genes that regulate angiogenesis at different phases.

In the present study, MP<sup>Shh+</sup> upregulated Rho A expression, as shown by western blot and confocal microscopy, and induced the phosphorylation of FAK that were reversed by both ROCK inhibitor and cyclopamine, suggesting a cross-link between ROCK and Shh pathways. Also, formation of stress fibers by MP<sup>Shh+</sup> was dependent of ROCK pathway as demonstrated by the lack of effects of MP<sup>Shh+</sup> when the ROCK inhibitor was present (data not shown). It has been shown that the activities of Rho A and ROCK are responsible for several effects of Shh activation (42,43). Paradoxically, MP<sup>Shh+</sup> increased endothelial cell adhesion by a mechanism sensitive to ROCK inhibitor but not cyclopamine. The lack of effect of cyclopamine in cell adhesion might be due to the complexity of this process or the implication of a mechanism independent to Smo receptor activation. Thus, Shh pathway may be involved in the activation of certain (here, Rho A and p-FAK), but not all, proteins implicated in the adhesion process. Nevertheless, MP<sup>Shh+</sup> enhanced endothelial cell adhesion indicating a role of these MPs in angiogenesis.

Both cell migration and proliferation were inhibited by MP<sup>Shh+</sup> and these effects were independent of Smo receptor activation, suggesting that although formation of capillary-like structures is promoted by MP<sup>Shh+</sup>, these MPs are able to differentially regulate cell events leading to angiogenesis. Similar results have been reported for the angiopoietin-like 4, which is able to promote angiogenesis (44) and inhibit endothelial cell migration by an interaction with the extracellular matrix (45). Moreover, it should be noted that the nature of all molecular components of MP<sup>Shh+</sup> is not known. Proteomic studies have shown that MPs composition is complex and dependent on the stimuli used for their generation as well as on the cell origin (46,47). In the present study, we have engineered MPs harboring Shh but other components are not determined and, obviously, they can influence angiogenesis.

In summary, MPs carrying Shh regulate multiple pathways related to *in vitro* angiogenesis, mainly through the production of proangiogenic factors and upregulation of proteins involved in cell adhesion. Expression of Shh correlates with the tumorigenesis of different types of cancer such as basal cell carcinoma, pancreatic and prostatic cancer and gliomas (48–51). In addition, release of MPs from tumor or vascular cells is also related with tumorigenesis. Thus, targeting Shh pathway would represent a novel therapeutic tool that can regulate angiogenesis and in consequence, tumor development.

## Funding

Fonds Européen pour le Développement Régional (8891 to R.A.); Agence Nationale pour la Recherche (ANR-07-PHYSIO-010-01 to M.C.M.); Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale et Université d'Angers.

## Acknowledgements

We thank L.Preisser and M.-H.Guillex from Service Commun de Cytométrie et d'Analyses Nucléotidiques from Institut Fédératif de Recherche 132 (Université d'Angers) for their assistance in quantitative PCR quantification and

R.Filmon from Service Commun d'Imagerie et d'Analyses Microscopiques (Université d'Angers). R.S. and T.B. are recipients of a doctoral fellowship from Italian and French Education Ministry (MENRT).

**Conflict of Interest Statement:** None declared.

## References

- Bailey, J.M. *et al.* (2007) Cancer metastasis facilitated by developmental pathways: Sonic hedgehog, Notch, and bone morphogenic proteins. *J. Cell. Biochem.*, **102**, 829–839.
- Olsen, C.L. *et al.* (2004) Hedgehog-interacting protein is highly expressed in endothelial cells but down-regulated during angiogenesis and in several human tumors. *BMC Cancer*, **4**, 43.
- Tenzen, T. *et al.* (2006) The cell surface membrane proteins Cdo and Boc are components and targets of the Hedgehog signaling pathway and feedback network in mice. *Dev. Cell*, **10**, 647–656.
- Kanda, S. *et al.* (2003) Sonic hedgehog induces capillary morphogenesis by endothelial cells through phosphoinositide 3-kinase. *J. Biol. Chem.*, **278**, 8244–8249.
- Pola, R. *et al.* (2001) The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. *Nat. Med.*, **7**, 706–711.
- Riobó, N.A. *et al.* (2006) Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling. *Proc. Natl Acad. Sci. USA*, **103**, 4505–4510.
- Fu, J.R. *et al.* (2006) Sonic hedgehog protein promotes bone marrow-derived endothelial progenitor cell proliferation, migration and VEGF production via PI 3-kinase/Akt signaling pathways. *Acta Pharmacol. Sin.*, **27**, 685–693.
- Kusano, K.F. *et al.* (2005) Sonic hedgehog myocardial gene therapy: tissue repair through transient reconstitution of embryonic signaling. *Nat. Med.*, **11**, 1197–1204.
- Asai, J. *et al.* (2006) Topical sonic hedgehog gene therapy accelerates wound healing in diabetes by enhancing endothelial progenitor cell-mediated microvascular remodeling. *Circulation*, **113**, 2413–2424.
- Taipale, J. *et al.* (2001) The Hedgehog and Wnt signalling pathways in cancer. *Nature*, **411**, 349–354.
- Pasca di Magliano, M. *et al.* (2003) Hedgehog signalling in cancer formation and maintenance. *Nat. Rev. Cancer*, **3**, 903–911.
- Ruiz i Altaba, A. *et al.* (2002) Gli and hedgehog in cancer: tumours, embryos and stem cells. *Nat. Rev. Cancer*, **2**, 361–372.
- Xie, J. *et al.* (2001) A role of PDGFR $\alpha$  in basal cell carcinoma proliferation. *Proc. Natl Acad. Sci. USA*, **98**, 9255–9259.
- Zedan, W. *et al.* (2001) Expression of the Sonic Hedgehog receptor "PATCHED" in basal cell carcinomas and odontogenic keratocysts. *J. Pathol.*, **194**, 473–477.
- Zwicker, J.I. *et al.* (2007) Cancer-associated thrombosis. *Crit. Rev. Oncol. Hematol.*, **62**, 126–136.
- Kanazawa, S. *et al.* (2003) Monocyte-derived microparticles may be a sign of vascular complication in patients with lung cancer. *Lung Cancer*, **39**, 145–149.
- Kim, H.K. *et al.* (2003) Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. *Eur. J. Cancer*, **239**, 184–191.
- Yu, J.L. *et al.* (2004) Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. *J. Thromb. Haemost.*, **2**, 2065–2067.
- Angelucci, A. *et al.* (2000) Vesicle-associated urokinase plasminogen activator promotes invasion in prostate cancer cell lines. *Clin. Exp. Metastasis*, **18**, 163–170.
- Millimaggi, D. *et al.* (2007) Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells. *Neoplasia*, **9**, 349–357.
- Janowska-Wieczorek, A. *et al.* (2006) Enhancing effect of platelet-derived microvesicles on the invasive potential of breast cancer cells. *Transfusion*, **46**, 1199–1209.
- Janowska-Wieczorek, A. *et al.* (2005) Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. *Int. J. Cancer*, **113**, 752–760.
- Kalinkovich, A. *et al.* (2006) Functional CXCR4-expressing microparticles and SDF-1 correlate with circulating acute myelogenous leukemia cells. *Cancer Res.*, **66**, 11013–11020.
- Martínez, M.C. *et al.* (2006) Transfer of differentiation signal by membrane microvesicles harbouring hedgehog morphogens. *Blood*, **108**, 3012–3020.



25. Agouni, A. et al. (2007) Sonic hedgehog carried by microparticles corrects endothelial injury through nitric oxide release. *FASEB J.*, **21**, 2735–2741.
26. Favot, L. et al. (2003) Involvement of cyclin-dependent pathway in the inhibitory effect of delphinidin on angiogenesis. *Cardiovasc. Res.*, **59**, 479–487.
27. Gross, I. et al. (2008) The intestine-specific homobox gene *Cdx2* decreases mobility and antagonizes dissemination of colon cancer cells. *Oncogene*, **27**, 107–115.
28. Vandesompele, J. et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. *Genome Biol.*, **3**, RESEARCH0034.
29. Qin, G. et al. (2006) Functional disruption of  $\alpha 4$  integrin mobilizes bone marrow-derived endothelial progenitors and augments ischemic neovascularization. *J. Exp. Med.*, **203**, 153–163.
30. Suzuki, K. et al. (1999) A novel glycosylphosphatidyl inositol-anchored protein on human leukocytes: a possible role for regulation of neutrophil adherence and migration. *J. Immunol.*, **162**, 4277–4284.
31. Griffioen, A.W. et al. (2000) Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. *Pharmacol. Rev.*, **52**, 237–268.
32. Ziche, M. et al. (1997) Nitric oxide lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. *J. Clin. Invest.*, **99**, 2625–2634.
33. Kim, I. et al. (2001) Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. *J. Biol. Chem.*, **276**, 7614–7620.
34. Krum, J.M. et al. (1998) VEGF mRNA and its receptor flt-1 are expressed in reactive astrocytes following neural grafting and tumor cell implantation in the adult CNS. *Exp. Neurol.*, **154**, 57–65.
35. Raffetto, J.D. et al. (2008) Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. *Biochem. Pharmacol.*, **75**, 346–359.
36. Solà-Vilà, D. et al. (2006) IL-1 $\beta$  induces VEGF, independently of PGE2 induction, mainly through the PI3-K/mTOR pathway in renal mesangial cells. *Kidney Int.*, **70**, 1935–1941.
37. Morishita, R. et al. (2004) Therapeutic angiogenesis using hepatocyte growth factor (HGF). *Curr. Gene Ther.*, **4**, 199–206.
38. Gordon, K.J. et al. (2008) Role of transforming growth factor- $\beta$  superfamily signaling pathways in human disease. *Biochim. Biophys. Acta*, **1782**, 197–228.
39. Denner, S. et al. (2007) Induction of sonic hedgehog mediators by transforming growth-beta: Smad3-dependent activation of Gli2 and Gli1 expression *in vitro* and *in vivo*. *Cancer Res.*, **67**, 6981–6986.
40. Lee, S.W. et al. (2007) Sonic hedgehog inversely regulates the expression of angiopoietin-1 and angiopoietin-2 in fibroblasts. *Int. J. Mol. Med.*, **19**, 445–451.
41. van Tuyl, M. et al. (2007) Angiogenic factors stimulate tubular branching morphogenesis of sonic hedgehog-deficient lungs. *Dev. Biol.*, **303**, 514–526.
42. Kasai, K. et al. (2004) The G12 family of heterotrimeric G proteins and Rho GTPase mediate Sonic hedgehog signaling. *Gene Cells*, **9**, 49–58.
43. Nishimaki, H. et al. (2004) A role of activated Sonic hedgehog signaling for the cellular proliferation of oral squamous cell carcinoma cell line. *Biochem. Biophys. Res. Commun.*, **314**, 313–320.
44. Le Jan, S. et al. (2003) Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma. *Am. J. Pathol.*, **162**, 1521–1528.
45. Cazes, A. et al. (2006) Extracellular matrix-bound angiopoietin-like 4 inhibits endothelial cell adhesion, migration, and sprouting and alters actin cytoskeleton. *Circ. Res.*, **99**, 1207–1215.
46. Miguet, L. et al. (2006) Proteomic analysis of malignant lymphocyte membrane microparticles using double ionization coverage optimization. *Proteomics*, **6**, 153–171.
47. Smalley, D.M. et al. (2007) Proteomic discovery of 21 proteins expressed in human plasma-derived but not platelet-derived microparticles. *Thromb. Haemost.*, **97**, 67–80.
48. Becher, O.J. et al. (2008) Gli activity correlates with tumor grade in platelet-derived growth factor-induced gliomas. *Cancer Res.*, **268**, 2241–2249.
49. Marsh, D. et al. (2008) Alpha vbeta 6 integrin promotes the invasion of morphoeic basal cell carcinoma through stromal modulation. *Cancer Res.*, **68**, 3295–3303.
50. Mimeault, M. et al. (2007) Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells. *Mol. Cancer Ther.*, **6**, 967–978.
51. Nakashima, H. et al. (2006) Nuclear factor-kappaB contributes to hedgehog signaling pathway activation through sonic hedgehog induction in pancreatic cancer. *Cancer Res.*, **66**, 7041–7049.

Received August 12, 2008; revised December 20, 2008;  
accepted January 18, 2009